LETTERS FOR ISSUE ON
|
|
|
- Norman Bailey
- 5 years ago
- Views:
Transcription
1 S FOR ISSUE ON BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ALEMBIC PHARMACEUTICALS 2. M/S. ALEMBIC PHARMACEUTICALS 3. M/S. ALEMBIC PHARMACEUTICALS 4. M/S. EMCURE PHARMACEUTICALS LIMITED, PUNE M/S. EMCURE PHARMACEUTICALS LIMITED, PUNE M/S. SYNCHRON RESEARCH SERVICES PVT. LTD., AHMEDABAD M/S. SYNGENE INTERNATIONAL LTD., BANGALORE TEST LICENCE 6047 TEST LICENCE 6046 TEST LICENCE 8495 AMENDMENT 706 AMENDMENT 8590 TEST LICENCE 6072 AMENDMENT NEW DRUG S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. HETERO LABS LTD., - IPC, QUERY 2. M/S. HONOUR LBAS LTD. - IPC, QUERY 3. M/S. SANDOZ PVT LTD., - IPC, QUERY 4. M/S. THEMIS MEDICARE LTD. - IPC, QUERY 5. M/S. ELI-LILLY COMPANY INDIA PVT LTD. 6. M/S. DR. REDDY S LABORATORIES LTD. - IPC, QUERY - QUERY
2 7. M/S. AKUMS DRUGS & - QUERY PHARMACEUTICALS LTD. 8. M/S. AJANTA PHARMA LTD., - QUERY 9. M/S. HEMMO PHARMACEUTICAL PVT LTD., - BIOLOGICAL DIVISION NAME OF COMPANY DY. NO. STATUS M/S RELIANCE LIFE SCIENCES PVT, LTD M/S BRISTOL MYERS SQUIBB INDIA PVT, LTD M/S SANOFI SYNTHELABO INDIA PVT, LTD 34442, 6321 APPROVAL & CLARIFICATION 5361 CLARIFICATION 5690 APPROVAL BA-BE S. NO NAME OF THE FIRM 1. M/S. VEEDA CLINICAL RESEARCH PVT. LTD., AMBEWADI, AHMEDABAD 2. M/S. VEEDA CLINICAL RESEARCH PVT. LTD., AMBEWADI, AHMEDABAD 3. M/S. LUPIN BIO RESEARCH CENTRE., PASHAN, PUNE 4. M/S. LUPIN BIO RESEARCH CENTRE., PASHAN, PUNE 5. M/S. RA CHEM PHARMA LTD., BALANAGAR, HYDERABAD FDC DIVISION S.NO. NAME OF COMPANY DIARY NO. DOCUMENT 1. M/S. ALLIANCE FORMULATIONS 7604/7605 S 2. M/S. AKUMS DRUGS & PHARMACEUTICALS 36725/36845/ S
3 LTD., 3. M/S. CIPLA LTD., 299/ S 4. M/S. NATCO PHARMA M/S. NANZ MED SCIENCES PHARMA M/S. AEON FORMULATIONS 1529/ S 7. M/S. WINDLAS BIOTECH 35854/33761/ S 8. M/S. ERIS LIFE SCIENCES 106/2665/136 2 S 9. M/S. MICRO LABS M/S. NEXT WAVE (INDIA) M/S. A.N. PHARMACIA LABORATORIES M/S. AURIO PHARMA M/S. ACCENT PHARMA M/S. MACSUR PHARMA (INDIA) M/S. ABBOTT HEALTHCARE 7817/ S 16. M/S. CACHET PHARMACEUTICALS M/S. INVENTIA HEALTHCARE M/S. AKSIGEN HOSPITAL CARE M/S. CENTAUR PHARMACEUTICALS M/S. TABLETS (INDIA) M/S. SUNGLOW PHARMACEUTICALS M/S. ALBERT DAVID S 23. M/S. G.M. PHARMACEUTICALS M/S. GENA PHARMA 3751 DIAGNOSTICS DIVISION S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. ALL CURE PHARMA PVT.LTD. FTS NO:-9124
4 2. M/S DSS IMAGETECH PVT.LTD. M/S SIEMENS LIMITED M/S BECKMAN COULTER INDIA PVT. LTD. M/S QIAGEN INDIA PVT. LTD. M/S ABBOTT HEALTHCARE PVT. LTD. THE DIRECTOR, NIB, NOIDA 3. SH.S.K.SARIN, DIRECTOR, INSTITUTE OF LIVER AND BILIARY SCIENCES (ILBS) 4. M/S VISHAT DIAGNOSTICS PVT. LTD APPROVAL (TL) MEDICAL DEVICE S.NO. COMPANY NAME DIARY NO STATUS 1. M/S PARAZELSUS INDIA PVT.LTD. FTS NO:-7642 CLARIFICATION 2. M/S INDIA HEALTH LINK PVT.LTD. FTS NO: /DCGI CLARIFICATION 3. M/S GLENMARK PHARMACEUTICAL LIMITED 5028 CLARIFICATION 4. M/S BSN MEDICAL PVT.LTD THE STATE DRUGS CONTROLLER, PANCHKULA (CLAA) THE DEPUTY DRUGS CONTROLLER, GHAZIABAD (CLAA) (M/S POLY MEDICURE LTD.) 6. THE DIRECTOR OF DRUGS CONTROL, CHENNAI (CLAA) THE DEPUTY DRUGS CONTROLLER, CHENNAI (CLAA) M/S SYNKROMAX BIOTECH PVT.LTD. (CLAA) FTS NO: APPROVAL 7. M/S PREGNA INTERNATIONAL LTD., 4613
5 COSMETICS DIVISION S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. NOVELTY IMPEX, DOMBIVALI, THANE, INDIA 4952 APPROVAL 2. M/S. VARIETY TRADERS, DOMBIVALI, THANE EAST, INDIA 4953 APPROVAL 3. M/S. VISHWAS TRADERS, BHIWANDI 5143 APPROVAL 4. M/S. D. M. ENTERPRISES, BHIWANDI 5142 APPROVAL 5. M/S. BRIO MERCANTILE PVT. LTD., MUMBAI 6247 APPROVAL 6. M/S. S.R. ENTERPRISES, THANE, MAHARASHTRA 5326 APPROVAL 7. M/S. BEAUTY CONCEPTS PVT. LTD., KOLKATA 5805 APPROVAL 8. M/S. HINDUSTAN UEVER LTD., ANDHERI (E), MUMBAI 1669 APPROVAL 9. M/S. OSIYAN LIFESCIENCES PVT. LTD., BANGALORE 8002 CANCELLATION OLD RC 10. M/S. SHOHAN CHEMICALS PVT. LTD., NEW DELHI DEFICIENCY 11. M/S. KIKO COSMETICS RETAIL PVT. LTD., GURGAON 6622 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 21.06.2016 LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY NO. STATUS 01 M/S. GLOBAL PHARMA HEALTHCARE PVT. LTD., THIRUPORUR 27509 APPROVAL BIOLOGICAL DIVISION NAME OF COMPANY DY.NO. STATUS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 11.04.2017 BIOLOGICAL DIVISION NAME OF COMPANY DY. NO. STATUS M/S ZUVENTUS HEALTHCARE LTD 6981 APPROVAL M/S TECHINVENTION LIFE SCIENCES 1208 CLARIFICATION M/S CADILA PHARMACEUTICALS LTD
LETTERS FOR ISSUE ON
S FOR ISSUE ON 04.12.2015 NEW DRUG S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. VIRCHOW BIOTECH PVT LTD - QUERY 2. M/S. MSN LABORATORIES PVT - CT-NOC & BE NOC LTD (3) 3. M/S. NATCO PHARMA LTD. - BE-NOC
LETTERS FOR ISSUE ON
S FOR ISSUE ON 14.03.2016 IMPORT S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. TABLETS (INDIA) LIMITED 5973 APPROVAL 2. TABLETS (INDIA) LIMITED 5974 APPROVAL 3. CLARIS OTSUKA PRIVATE LIMITED 7373 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 03.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S LUPIN TARAPUR, MAHARASHTRA & WC 2. M/S JPN PHARMA PVT. PALGHAR, MAHARASHTRA WC 3. M/S OPTIMUS DRUGS A.P. WC VACCINE DIVISION S.
LETTERS FOR ISSUE ON
S FOR ISSUE ON 29.11.2016 COSMETICS DIVISION S.NO. NAME OF APPLICANT DIARY NO. TYPE OF 1. M/S. WELLA INDIA PVT. LTD., MUMBAI 29233, 29524 & 28513 APPROVAL 2. M/S. PROCTER & GAMBLE HOME PRODUCTS PVT. LTD.,
LETTERS FOR ISSUE ON
S FOR ISSUE ON 04.10.2017 MEDICAL DEVICE DIVISION S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. ABBOTT MEDICAL OPTICS PVT. LTD., 14608 QUERY 2. M/S. ABBOTT MEDICAL OPTICS PVT. LTD., 14609 QUERY 3. DR. ULHAS
LETTERS FOR ISSUE ON
S FOR ISSUE ON 15.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1 M/S NATCO PHARMA LIMITED HYDERABAD MEDICAL DEVICE S.NO. COMPANY NAME DIARY NO STATUS 1. M/S. GENETIX BIOTECH ASIA PVT. LTD. 22073 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 01.09.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE 1. M/S TYCHE INDUSTRIES LTD., ANDHRA PRADESH, INDIA IMPORT S. NAME OF APPLICANT DIARY TYPE OF 1. PIRAMAL ENTERPRISES LTD. 25471 APPROVAL
LETTERS FOR ISSUE ON
S FOR ISSUE ON 19.06.2015 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT., NAVI MUMBAI-400 709 2. M/S. ACCUTEST RESEARCH LABORATORIES (I) PVT.,
LETTERS FOR ISSUE ON
S FOR ISSUE ON 14.12.2015 LVP DIVISION S. COMPANY NAME FTS /DIARY STATUS 01 M/S. AXA PARENTERALS LTD., ROORKEE 60262 APPROVAL 02 M/S. UNIJULES LIFE SCIENCES LTD., NAGPUR 61147 APPROVAL 03 M/S. INNVOL MEDICAL
TODAY LETTER DATED
TODAY LETTER DATED 26.06.2018 GLOBAL CLINICAL TRIAL SR. NO. COMPANY NAME REFERENCE NO. STATUS 1 M/S. RESEARCH ASSOCIATES INDIA PVT.. 18670 PA APPROVAL LETTER LVP DIVISION S. NO. COMPANY NAME FTS NO. /DIARY
LETTERS FOR ISSUE ON
S FOR ISSUE ON 05.10.2015 INTERNATIONAL CELL S. NO FIRM NAME TYPE OF DOCUMENT 1. M/S. ARRIGO INTERNATIONAL,INDORE 2 M/S. EUROLIFE HEALTHCARE PVT. LTD. HARIDWAR NEW DRUG S. NAME OF APPLICANT DIARY TYPE
LETTERS FOR ISSUE ON
S FOR ISSUE ON 17.05.2016 BE NOC FOR EXPORT S. NO. NAME OF THE COMPANY REF. NO. TYPE OF 1. M/S. ACCUTEST RESEARCH MUMBAI-400709 2. M/S. ACCUTEST RESEARCH MUMBAI-400709 3. M/S. ACCUTEST RESEARCH MUMBAI-400709
LETTERS FOR ISSUE ON
S FOR ISSUE ON 17.07.2015 NEW DRUG S.NO. NAME OF APPLICANT DIARY TYPE OF NO. 1. M/S. CIREX PHARMACEUTICALS LTD - QUERY 2. M/S. LUPIN LIMITED - ADDITIONAL SITES REGISTRATION S.NO. NAME OF APPLICANT DIARY
LETTERS FOR ISSUE ON
LETTERS FOR ISSUE ON 27.12.2017 LVP DIVISION S. NO. COMPANY NAME FTS NO. /Diary No. STATUS 01 M/s. Akums Drugs & Pharmaceuticals, Haridwar 02 M/s. Unique Pharmaceutical Laboratories,Guj. (License No.4)
LETTERS FOR ISSUE ON
S FOR ISSUE ON 27.08.2015 NEW DRUG S. NAME OF APPLICANT DIARY TYPE OF 1. M/S. INTAS PHARMACEUTICALS LIMITED - CT NOC (2) 2. M/S. PFIZER LIMITED - QUERY 3. M/S. MSN LABORATORIES - ADDITIONAL SITE 4. M/S.
New Delhi, the 18 th December, 2017 ORDER
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
Minimumum Price (Rs.) 3.30 Maximum Price (Rs.) 4.57 Average of all considered (Rs.) 3.73 Retail Price (Rs.) 4.33
Computataion of Retail Price based on Jan.-2016 Data under Para 4 of DPCO 2013 Cholecalciferol 800 IU Drops of M/s Raptakos, Brett & Co.Ltd. Number of Companies cosisting of Market Share of 1% & Above
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 01/03/2016 to 29/04/2016
1. M/s LG Life Sciences India Pvt. Ltd.,Basement Commercial SCO No. 321, Sector-29, Gurgaon, India 2. M/s Eli Lilly and Co (I) Pvt. Ltd., Bldg. No. 14, Gala No. 1 to 4, 1 st Fl, Arihant Comm. Complex,
Recommendations of thesec (Dermatology & Allergy) made in its 23 rd meeting held on at CDSCO HQ New Delhi: New Drugs Division
Recommetions of thesec (Dermatology & Allergy) made in its 23 rd meeting held on 11.05.2017 at CDSCO HQ New Delhi: File /Drug Name Recommetions New Drugs Division 1 12-28/15-DC (Pt-B) Apremilast 10/20/30
File no./drug Name Name of firm/ Institute Recommendations. New Drugs Division
Recommendations: I approve the minutes of 52 nd SEC (Oncology & hematology) held on 13.04.2017 at CDSCO HQ New Delhi and recommended the following: Agenda 1 12-63/16-DC Ferric Pyrophosphate citrate solution
ORDER. Table. (1) (2) (3) (4) (5) (6) 1. Glimepiride Metformin Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of National Pharmaceutical Pricing Authority
ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Rosuvastatin + Clopidogrel Capsule (Crevast CV 20)
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical
RESULTS AND DISCUSSION
RESULTS AND DISCUSSION 203 4.1 General Introduction: The researcher has collected both the primary and secondary data. The primary data is collected by direct interaction by using formal questionnaire
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013
Subject: Consolidated list of all cases of price fixation of new drugs received from various companies under para 5 of DPCO 2013 Sl. No. F.No. Name of the Company/ Formulation Date of receipt of application
TOTAL MAT 1,52,81, % Unit PTR (Rs.) MAT (Rs.) SKU wise MAT % प क व रण Pack Description छ प BRAND. क पन Company. S. No. Unique No.
Number of Companies consisting of Market Share of 1% & Above 2 3.1 Adrenaline Injection 1 mg/ml Per ml Sum of MAT value considered for price calculation (in Lakhs) 152.69 Sum of PTR per unit considered
ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Teneligliptin Hydrobromide + Metformin HCL (SR) Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of s National Pricing Authority ORDER New
Recommendations: Agend a no. Recommendations. Institute. New Drugs Division /12-DC ArbekacinSulphate Injection 200mg/4ml
: I approve the minutes of 32 nd SEC (Antimicrobial, Antiviral, Antiparasitic and Antifungal) held on 11.04.2017 at CDSCO HQ New Delhi and recommended the following: Agend New Drugs Division 1 12-34/12-DC
What s New
What s New 23.12.2016 NPPA has fixed/revised ceiling prices of 55 scheduled formulations of Schedule-I under Drugs ( Control) Amendment Order,2016 and Retail of 29 formulations under DPCO, 2013 in related
ORDER. Table. Retail Price (Rs.) (1) (2) (3) (4) (5) (6) 1. Rosuvastatin Clopidogrel Tablet
(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary) Government of India Ministry of Chemicals and Fertilizers Department of Pharmaceuticals National Pharmaceutical
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 30/04/2016 to 20/12/2016
Status of Import License (Form 10) of Recombinant Products, Human and Veterinary Vaccines issued from 30/04/2016 to 20/12/2016 RECOMBINANT PRODUCTS S. No. Firm Name of Formulation Import License No. &
CHAPTER FOUR: UPDATE ON THE AIDS PANDEMIC TABLE 2 MILESTONES IN THE HISTORY OF HIV/AIDS TABLE 2 (CONTINUED) REGIONAL OVERVIEW...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THE STUDY... 1 SCOPE OF REPORT... 1 MARKET ANALYSES AND FORECASTS... 2 INTENDED AUDIENCE... 2 INFORMATION SOURCES... 2 ANALYST
Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on and recommended the following:-
Recommendation:- The 19 th SEC - (Oncology & Hematology) deliberated the proposals on 05.11.2014 and recommended the following:- Agend a No. File No. 1. File No.: 12-75/13-DC Afatinib film coated tablet
New: Li st of TPAs List of TPA's released by IRDA Updated C on Oct lick Here.
TPA List In India // Third Party Administrators for Health Insurance are a link between the insured A Third Party Administrator is the same as an ASO - administrative services only company. The duties
Companies Database, Mobile Database, Id Database, Credit
m All India Database We Provides Database Companies Database, Mobile Database, Email Id Database, Credit Card Holder Database, Corporate database, CEO s Database, Corporate Employee Database, Car s Owner
BRIC DIABETES DRUGS MARKET
BRIC DIABETES DRUGS MARKET R e p o r t D e s c r i p t i o n T a b l e o f C o n t e n t s L i s t o f T a b l e s S a m p l e T a b l e s R e l a t e d R e p o r t s A b o u t M a r k e t s a n d M a
3. Dr.Rajutitus Chacko, Prof. & Head, Dept. of Medical Oncology, CMC, Vellore.
MINUTES OF THE 6 th MEETING OF TECHNICAL COMMITTEE HELD ON 25-07-2013 UNDER CHAIRMANSHIP OF DGHS FOR SUPERVISING CLINICAL TRIALS ON NEW CHEMICAL ENTITIES IN THE LIGHT OF DIRECTIONS OF THE HON BLE SUPREME
Status of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015. Human vaccines
Status of Registration Certificate (Form 41) of Human Vaccines issued from 01/03/2015 to 29/05/2015 S. No. Firm Name of Formulation Registration Certificate No. & Validity 1. M/s. Nirlac Chemicals,14 th
TRADE MARKS REGISTRY AHMEDABAD
TRADE MARKS REGISTRY AHMEDABAD OPPOSITION HEARING LIST FOR THE MONTH OF JUNE-2016 DATE OF HEARING 13.06.2016 1. 934855/05 Opp. AMD-245342 M/s. Ajanta Pharma Limited, Mumbai / Mr. Manoj G. Menda, Mumbai
Global Aspergillosis Drugs Market Professional Survey Report 2016
Report Information More information from: https://www.wiseguyreports.com/reports/526011 Global Aspergillosis Drugs Market Professional Survey Report 2016 Report / Search Code: WGR526011 Publish Date: 24
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 19 Apr 2019 13:49:20 GMT) CTRI Number CTRI/2009/091/000126 [Registered on: 15/04/2009] - Last Modified On 03/09/2014 Post Graduate Thesis Type of Trial
New Drugs Division. Frequently Asked Questions (FAQs) on Approval of new Phytopharmaceutical Drugs
Central Drugs Standard Control Organization Directorate General of Health Services Ministry of Health and Family Welfare Government of India New Drugs Division Frequently Asked Questions (FAQs) on Approval
10 th SEC- (Reproductive & Urology)meetingheld on at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi PROGRAMME SCHEDULE
10 th SEC- (Reproductive & Urology)meetingheld on 16-01-2015 at CDSCO (HQ), FDA Bhawan, Kotla road, New Delhi 110 002 PROGRAMME SCHEDULE Recommendation:- The 10 th SEC (Reproductive and Urology) meeting
Ameya works predominantly in the architectural design, interiors and project management segments in healthcare industry
Introduction Ameya design is premier health care consultancy firm with experience with design and execution of largest number of private sector health care facility in India. Key Information Ameya works
PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
1 Agio Pharmaceuticals Limited 15/31/2013-EP(Engg) dt:21.11.2013 7,98,217.00 2 Akriti Pharmaceuticals Pvt Ltd 15/31/2013-EP(Engg) dt:21.11.2013 15,10,268.00 3 Akriti Pharmaceuticals Pvt Ltd 15/31/2013-EP(Engg)
1. Dr. Shyam Agarwal, Joint Secretary, Department of Commerce. 2. Shri A.K. Bamba, Director, Department of Commerce
Minutes of Meeting of Inter Ministerial Committee (IMC) for consideration of proposals for setting up ICDs / CFSs held under Chairmanship of Shri P.K. Chaudhery, Additional Secretary (AS), Department of
Edmund Healthcare Pvt. Ltd.
+91-8048410921 Edmund Healthcare Pvt. Ltd. https://www.edmundhealthcare.in/ Our firm is ranked as the leading Trader and Supplier of a wide array of Pharmaceutical Injection, Pharmaceutical Tablets, Pharmaceutical
List Of Antihepatitis Pharmaceutical Products (included to support Global Fund Policy for Co-Infections and Co-Morbidities)
Edition: Version 11-19th of July 2018 List of A & B Products List Of Antihepatitis Pharmaceutical Products (included to support Global Fund Policy for Co-Infections and Co-Morbidities) As from the version
INDICATIVE SEAT MATRIX - NBE FET CENTRALIZED COUNSELING 2016 ADMISSION SESSION ROUND-2
G B Pant Hospital J L Nehru Marg, Delhi Cardiac Anaesthesia 1 Delhi-110002 Indraprastha s Delhi Cardiac Anaesthesia 1 Medanta- The Medicity Sector-38, Gurgaon, Haryana Cardiac Anaesthesia 5 Haryana-122001
NPPA has fixed/revised ceiling prices/retail prices of 22 formulations under Drugs (Prices Control) Order,
What s New 12.06.2018 NPPA has fixed/revised ceiling prices/retail prices of 22 formulations under Drugs (Prices Control) Order, 2013 NPPA has fixed/revised ceiling prices/retail prices of 22 formulations
MEETING OF DRUGS TECHNICAL ADVISORY BOARD HELD ON 1 ST APRIL, 2014 IN THE CHAMBER OF DGHS, NIRMAN BHAWAN, NEW DELHI
MINUTES OF THE 67 TH MEETING OF DRUGS TECHNICAL ADVISORY BOARD HELD ON 1 ST APRIL, 2014 IN THE CHAMBER OF DGHS, NIRMAN BHAWAN, NEW DELHI PRESENT 1. Dr. Jagdish Prasad, Chairman Director General of Health
PHARMACEUTICALS EXPORT PROMOTION COUNCIL OF INDIA
Disbursement of MDA Claims to Individual Exporters during (-11) 1 JPN Pharma API China 80,000.00 2 Unique Biotech Limited Bio May 3-6, 80,000.00 3 Titan Biotech Limited Cphi Japan 21st to 23rd April 80,000.00
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 05 Oct 2018 20:16:50 GMT) CTRI Number Last Modified On 07/08/2014 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Exporting Heart Disease to Developing Countries: India. Zeeshan Ali, Ph.D.
Exporting Heart Disease to Developing Countries: India Zeeshan Ali, Ph.D. Mortality Rate Heart disease is the number one cause of mortality. Accounts for one-fourth of all deaths in India. Source: Gupta
Name of firm/applicant. Torrent Pharmaceuticals. Glenmark Pharmaceuticals. M/s. Torrent Pharmaceutical. Torrent Pharmaceuticals
Recommendation:- The 14 Th SEC (Cardiovascular & Renal) deliberated the proposals on 21.08.2014 and recommended the following:- Agenda no. File no Name of firm/applicant Recommendations 1. 04-228/06-D(pt
M/s. Hetero Labs Ltd.
:- The 1 st SEC (Gastroenterology&Hepatology) meeting deliberated the proposals on 06.01.2017 and recommended the following:- Agenda New Drugs Division Proposal 1 12-54/16-DC Sofosbuvir and Velpatasvir
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database
A study on Metformin (1, 1-Dimethylbiguanidemonohydrochloride) reported adverse events as observed in Eudravigilance database Contract Research Organization / Terzetto Pharma Metrics NIVETHA CHELLAPATHY
BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS
BOTANICAL AND PLANT-DERIVED DRUGS: GLOBAL MARKETS BIO022G August 2015 Kim Lawson Project Analyst ISBN: 1-62296-134-X BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
Education. Current Activities
Nirali Mehta, M.Sc., M.Phil. Founder & Consultant Biostatistician Ahmedabad, Gujarat, India. M +91 9377060504 E nirali.mehta@pharma-stats.in W www.pharma-stats.in Education 1998-2001 Bachelor of Science
Information for Vermont Prescribers of Prescription Drugs Long Form Fetzima (levomilnacipran) Extended Release Capsules
Information for Vermont Prescribers of Prescription Drugs Long Form Fetzima (levomilnacipran) Extended Release Capsules The prices listed below are Average Wholesale Prices ( AWP ) as established and made
Solvay in India January, 2014
Solvay in India January, 2014 SOLVAY in India, Innovation and Operational excellence Jodhpur Hichem (JV) Ahmedabad Hichem (JV) Bhiwani Hichem (JV) Delhi Hichem (JV) Solvay R&D center Vadodara Panoli Solvay
Decisions taken in the 63 rd Meeting of the Genetic Engineering Approval Committee (GEAC) held on 8 th February 2006.
Decisions taken in the 63 rd Meeting of the Genetic Engineering Approval Committee (GEAC) held on 8 th February 2006. The 63 rd Meeting of the Genetic Engineering Approval Committee was held on 8 th February
Case 2:09-cv DMC-CCC Document 1 Filed 03/20/2009 Page 1 of 95. Of Counsel:
Case 2:09-cv-01302-DMC-CCC Document 1 Filed 03/20/2009 Page 1 of 95 Charles M. Lizza William C. Baton SAUL EWING LLP One Riverfront Plaza Newark, NJ 07102 (973) 286-6700 clizza@saul.com Attorneys for Plaintiff
Vascular Endothelial Growth Factor Inhibitor Market
May 2017 Report Id : REP-GB-3292 Status : Ongoing Category : Healthcare, Pharmaceuticals & Medical Devices 2015 Future Market Insights, All Rights Reserved About Future Market Insights Future Market Insights
REF/2012/01/ CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 05 May 2018 05:20:32 GMT) CTRI Number Last Modified On 06/04/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Ms channel weight chart
Ms channel weight chart SS303, SS304, 304L, 308, 309, 309L, 310, 316, 316L, 321. MAHAVIR STEEL INDUSTRIES developes specific sections. Specific sizes in any section can be developed for economical and
FROST & SULLIVAN. Publications Division - Terms and Conditions of Business
FROST & SULLIVAN Publications Division - Terms and Conditions of Business 1. Frost & Sullivan and FICCI takes no responsibility for any incorrect information supplied by manufacturers or users. Quantitative
Narcotics Control Bureau
Narcotics Control Bureau 2 MARCH - 2015 MARCH - 2015 3 Narcotics Control Bureau SN Date Zone/Sub Zone Drug Seized Qty.(Kg) Indians Arrested 1 31.01.2015 Ahmedabad Alprazolam tab 272.522 Methylphenidate
Tamsulosin Hydrochloride 0.4 mg Capsule
Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule
Medicines availability short-term supply issues Last updated 01/05/18
Short-term supply issues This resource includes availability information on medicines that are reported to have supply issues, with next expected availability within the next three months. This list is
Generic HCV DAAs. Economics and sustainability. Dr. Andrew Hill Pharmacology and Therapeutics University of Liverpool, UK
Generic HCV DAAs Economics and sustainability Dr. Andrew Hill Pharmacology and Therapeutics University of Liverpool, UK Sunday, 23rd July 2017 Paris, France www.iasociety.org HCV DAAs can be made very
Nitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam
Nitrazepam, Nitrazepam India, Nitrazepam manufacturers India, side effects Nitrazepam manufacturers, Taj Pharma India, Nitrazepam overdose, Nitrazepam drug, Nitrazepam composition, Manufacturing Pharmaceutical,
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Thu, 18 Oct 2018 14:39:26 GMT) CTRI Number Last Modified On 06/04/2018 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 07 Oct 2018 22:54:26 GMT) CTRI Number Last Modified On 11/05/2018 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Doing Business in India; Nutritional ingredients supplier perspective. Jaime Piza DSM Nutritional Products November, 2012
Doing Business in India; Nutritional ingredients supplier perspective Jaime Piza DSM Nutritional Products November, 2012 Table of contents Doing business IFC classification. Still some hurdle to take...
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Tue, 16 Apr 2019 09:11:00 GMT) CTRI Number Last Modified On 04/10/2013 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 07 Oct 2018 14:20:17 GMT) CTRI Number Last Modified On 13/02/2014 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
WHO PUBLIC INSPECTION REPORT (WHOPIR) Contract Research Organization
SOP 408.4 Annex C 20, avenue Appia CH-1211 Geneva 27 Switzerland Tel central +41 22 791 2111 Fax central +41 22 791 3111 www.who.int Part 1: General information WHO PUBLIC INSPECTION REPORT (WHOPIR) Contract
Subsequent New Drugs Division. M/s.Troikaa. M/s. Olive Healthcare. Biological Division. M/s. Wockhardt Ltd. Global Clinical Trial Division
: The34 th SEC (Endocrinology & Metabolism) meeting held on 25.04.2017 at CDSCO HQ New Delhi and recommended the following: Age Subsequent New Drugs Division 1 12-146/2016-DC (Pt- Zim-Snd) Vitamin D3 (Cholecalciferol)
NOTIFICATION NO Different cooling off periods applicable for re-admission to Bureau membership - Publisher Members
Audit Bureau Of Circulations Founder Member : International Federation Audit Bureaux Circulations Wakefield House, Sprott Road, Ballard Estate, Mumbai 400 001 Tel: 2261 18 12 / 2261 90 72. Fax: 2261 88
Excipient Regulations Perspective & Creation of IPEC India (Current Regulations & Emerging challenges for excipient regulations in India)
INTERNATIONAL PHARMACEUTICAL EXCIPIENTS COUNCIL OF INDIA (IPEC INDIA) Excipient Regulations Perspective & Creation of IPEC India (Current Regulations & Emerging challenges for excipient regulations in
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Fri, 23 v 2018 09:27:36 GMT) CTRI Number Last Modified On 30/06/2016 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study Scientific
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 02 Sep 2018 23:38:24 GMT) CTRI Number Last Modified On 05/02/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
https://www.indiamart.com/max-pharma/
+91-8048603315 Max Pharma https://www.indiamart.com/max-pharma/ We are one of the leading organizations engaged in manufacturing and supplying a wide range of Pharmaceutical Drugs. These include Tablets,
Update on the Medicines Patent Pool
Update on the Medicines Patent Pool Sandeep Juneja November 06, 2012 How the Pool works* The Pool is an innovative licensing mechanism for HIV medicines Licensors Patents Feedback Market Impact Product
REF/2014/04/ CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 02 May 2018 19:38:55 GMT) CTRI Number Last Modified On 13/12/2014 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
Guidance on Performance Evaluation of In-vitro Diagnostic Medical Devices
Dated:- 07-Aug-2018 Guidance on Performance Evaluation of In-vitro Diagnostic Medical Devices As per the proviso of Clause (h), Paragraph (ii), part II of Fourth Schedule of Medical Devices Rules 2017,
Annexure. Reason for failure with Report No. (in Form-13)& Date Misbranded Report No / Dated
Annexure List of Drugs, Medical Devices and Cosmetics declared as Not of Standard Quality/Spurious/Adulterated/, For the Month of September, 2014 Sl. No. Name of Drugs/medica l device/cosmet ics 1 Paracetamol
Indian Pharmacopoeia Commission
Indian Pharmacopoeia Commission JP 130 th Anniversary Symposium Tokyo, Japan 15 th Sept, 2016 Dr.G.N.Singh Secretary cum Scientific Director, Overview Indian Pharmaceutical Industry Pharmacopoeia and NFI
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sun, 17 Mar 2019 03:23:33 GMT) CTRI Number Last Modified On 03/02/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
PDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Sat, 09 Mar 2019 16:29:06 GMT) CTRI Number CTRI/2010/091/000679 [Registered on: 23/08/2010] - Last Modified On 10/07/2015 Post Graduate Thesis Type of Trial
Regulatory Reforms-Future of Plasma Protein Therapy in India
Regulatory Reforms-Future of Plasma Protein Therapy in India Ranjeet S. Ajmani PlasmaGen BioSciences Pvt. Ltd. Bangalore, India PPB-2013 Price Tag of Contrast q Uniqueness q Co-existence : Rich & Poor
Information for Vermont Prescribers of Prescription Drugs
Information for Vermont Prescribers of Prescription Drugs ZOLOFT (sertraline hydrochloride) tablets, for oral use This list does not imply that the products on this chart are interchangeable or have the
Recent trends and challenges
INTERNATIONAL CONFERENCE ON Recent trends and challenges in Bioanalysis Tentative Program Bioanalytica-2017 Hyderabad,India JUNE 30, 2017 Invitation ABC Biologics welcomes you to attend the international
PDF of Trial CTRI Website URL -
CTRI Website URL http://ctri.nic.in Clinical Trial Details (PDF Generation Date : Tue, 21 Aug 2018 05:05:28 GMT) CTRI Number Last Modified On 03/12/2013 Post Graduate Thesis Type of Trial Type of Study
Access to Healthcare for Women and Children. A Philips CSR Initiative. Sumathi/ Anoop 8/31/17 An overview
Access to Healthcare for Women and Children A Philips CSR Initiative Sumathi/ Anoop 8/31/17 An overview A BRIEF ABOUT THE COMPANY PHILIPS INDIA LTD About Philips Philips India Limited is a subsidiary of
Public Assessment Report Scientific discussion. Vixantus (tadalafil) SE/H/1532/01-04/DC
Public Assessment Report Scientific discussion Vixantus (tadalafil) SE/H/1532/01-04/DC This module reflects the scientific discussion for the approval of Vixantus. The procedure was finalised on 2016-04-20.
MEDICATED / PERFUMERY OIL (CASTOR OIL DERIVATIVE)
Profile No.: 48 NIC Code: 20234 MEDICATED / PERFUMERY OIL (CASTOR OIL DERIVATIVE) 1. INTRODUCTION 2-Octanol is an eight carbon containing secondary Octyl alcohol, (also known as Capryl alcohol), or 2-Octyl